Teva Canada announces new auto-injector for Ajovy for the preventive treatment of migraine in adults

8 April 2021 - Ajovy now offers patients greater flexibility with two dosing options available in both an auto-injector and a ...

Read more →

Taltz (ixekizumab) approved by Health Canada for the treatment of paediatric patients (six to less than 18 years of age) with moderate to severe plaque psoriasis

2 April 2021 - On 29 March 2021, Health Canada issued a Notice of Compliance for Taltz (ixekizumab) injection, 80 mg/mL, ...

Read more →

Health Canada taking further action to confirm the benefit-risk profile of the AstraZeneca vaccine

29 March 2021 - As part of Health Canada’s continuing commitment to openness and transparency on all information relating to ...

Read more →

Canada urges halt in use of AstraZeneca COVID-19 vaccine in people under 55

30 March 2021 - Canadian authorities recommended Monday a halt on administering the AstraZeneca PLC COVID-19 vaccine on people under ...

Read more →

Seqirus ready to reinforce Canada's influenza pandemic preparedness plans

23 March 2021 - Health Canada's approval of Foclivia (an adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine) meets key requirement ...

Read more →

Health Canada says AstraZeneca shot is safe as U.S. questions vaccine's clinical trial data

23 March 2021 - U.S. regulator says AstraZeneca may have included 'outdated' data when releasing clinical trial results. ...

Read more →

Health Canada approves Kesimpta, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis

23 March 2021 - Approval is based on two Phase 3 studies (ASCLEPIOS I & II) demonstrating significant reductions in risk ...

Read more →

Seqirus announces Health Canada approval of expanded age indication of its cell-based quadrivalent influenza vaccine for people two years of age and older

18 March 2021 - Seqirus announced that Health Canada has approved Flucelvax Quadrivalent (influenza vaccine), its cell-based quadrivalent influenza vaccine, for ...

Read more →

Novartis' Kisqali (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer

18 March 2021 - Kisqali is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key ...

Read more →

Health Canada approves new indication for lung cancer treatment option Alunbrig

17 March 2021 - First-line indication offers Canadians with advanced lung cancer new treatment options. ...

Read more →

Health Canada approves Increlex, first and only recombinant human insulin-like growth factor-1 therapy in Canada for the treatment of severe growth failure associated with ultra rare condition in children and adolescents

16 March 2021 - Ipsen Biopharmaceuticals today announced the commercial availability of Increlex (mecasermin) for the treatment of growth failure in ...

Read more →

Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer

16 March 2021 - New approval provides Canadian patients with HER2 positive early breast cancer a proven treatment regimen in a ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for adults with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer

8 March 2021 - Approval based on significant progression-free survival findings from Phase 3 KEYNOTE-177 trial. ...

Read more →

Canada authorises one-shot COVID-19 vaccine from Johnson & Johnson

5 March 2021 - The first one-shot COVID-19 vaccine from Johnson & Johnson has been authorized by Health Canada, making ...

Read more →

Health Canada approves Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia

2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib. ...

Read more →